US Patent

US11752137 — Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

Formulation · Assigned to Tarsus Pharmaceuticals Inc · Expires 2038-12-14 · 13y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions for treating or preventing ophthalmic and dermatologic conditions, including ocular surface conditions, using isoxazoline or formamidine parasiticides.

USPTO Abstract

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US11752137
Jurisdiction
US
Classification
Formulation
Expires
2038-12-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Tarsus Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.